FULL TEXT ARTICLE DOI: 10.1056/NEJMoa2502866 Authors: David B Meya, Fiona V Cresswell, Biyue Dai, Nicole Engen, Kogieleum Naidoo, Ahmad Rizal Ganiem, Darma Imran, Mable Kabahubya, Richard J Lessells, Vycke Yunivita, Riwanti Estiasari, Lillian Tugume, Bongeka Hlabisa, Media Yuni Kurniawati, Noveline Sagita, Enock Kagimu, Kartika Maharani, Jane Gakuru, Maula N Gaharu, Timothy Mugabi, Sarah Kimuda, Suzan Namombwe,...Read More
FULL TEXT ARTICLE DOI: 10.12688/f1000research.28262.2 Authors: Evy Yunihastuti, Lusiani Rusdi, Muhammad Syahrir Azizi, Riwanti Estiasari, Chyntia Olivia Maurine Jasirwan, Endah Ayu T. Wulandari, Dyah Purnamasari, Mutiara Shinta Noviar, Sally Aman Nasution Background: Persistent immune activation and inflammation in HIV-infection are linked to excess cardiovascular risk and other non-communicable diseases. Periodic asymptomatic CMV-reactivity in HIV infected...Read More
PROTOCOL DOI: 10.1136/bmjopen-2023-076713 Authors: Riwanti Estiasari, Amanda Tiksnadi, Dyah Tunjungsari, Kartika Maharani, Tiara Aninditha, Henry Riyanto Sofyan, Irma Savitri, David Pangeran, Ivan Jeremia, Alvina Widhani, Anna Ariane Background: Chronic headache is a ‘silent’ neuropsychiatric systemic lupus erythematosus symptom with heterogeneous prevalence, potentially reaching 54.4%. It may reduce quality of life by increasing the likelihood of...Read More
PROTOCOL Type of study: Phase III interventional clinical trial Study design: This was a multicenter, double-blind, randomized, placebo-controlled Phase III clinical trial conducted across Indonesia, South Africa, and Uganda between June 2019 and May 2023. Adults with tuberculous meningitis, with or without HIV coinfection, were randomly assigned to receive either high-dose rifampin (35 mg/kg/day) or standard-dose...Read More
